Seagen’s potential breast cancer blockbuster Tukysa shows promise in colorectal cancer
Seattle-based biotech company Seagen revealed successful top-line results from a trial using cancer drug Tukysa plus chemotherapy, two years after its initial approval.
The treatment proves to be a promising first step in treating breast cancer and Seagen hopes to expand its use to colorectal cancer patients. The trial met its primary goal after 117 individuals received the therapy, with 38 percent seeing a complete or partial response resulting in a median group duration of 12.4 months without tumor growth.
Seagen intends to submit a new drug application to the FDA under the accelerated approval procedure.